Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    YM BIOSCIENCES INC.
    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars, unless otherwise indicated)

    -------------------------------------------------------------------------
                                                    March 31,        June 30,
                                                        2010            2009
    -------------------------------------------------------------------------
                                                  (Unaudited)
    Assets

    Current assets:
      Cash                                      $  27,862,417  $   2,337,716
      Short-term deposits                          20,149,367     39,713,042
      Accounts receivable                             390,714        564,584
      Prepaid expenses                                129,589        352,850
      -----------------------------------------------------------------------
                                                   48,532,087     42,968,192

    Property and equipment                             95,794         96,876

    Intangible assets                              14,982,168      3,004,868

    -------------------------------------------------------------------------
                                                $  63,610,049  $  46,069,936
    -------------------------------------------------------------------------
    ---------------------------
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... April 29 HEALTHeCAREERS Network , North America ... , , , ... ) , , , ... Cardiovascular Angiography and Interventions (SCAI) recently joined the Network, launching the ...
... MONACO , April 29, 2010 At the ... held in Monaco on March,12-13, 2010 , ... of the Euro,PDT, described the current state of topical photodynamic ... He also underscored the major role played by the Euro ...
... ... a drug safety services and pharmacovigilance training provider, will be speaking ... Michelle Flewell, CPLP, Vice President of eLearning and Informatics, will present ... management system (LMS) to create online pharmacovigilance training courses for the ...
Cached Biology Technology:Healthcare Web site Expands Reach to Cardiology Professionals 2Healthcare Web site Expands Reach to Cardiology Professionals 3Therapeutic Revolution in Dermatology 2Therapeutic Revolution in Dermatology 3Therapeutic Revolution in Dermatology 4Drug Safety Firm BioSoteria to Present on eLearning Development Experience 2Drug Safety Firm BioSoteria to Present on eLearning Development Experience 3
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... animal kingdom and they have largely remained a mystery ... the University of Exeter have uncovered the migratory secrets ... results could have huge implications for strategies to protect ... Biology, Dr Brendan Godley and an international team describe ...
... the Institut de recherches cliniques de Montréal (IRCM) ... that determines susceptibility to candidiasis, a common and ... human immunodeficiency virus (HIV). These findings, revealed using ... HIV developed by the same research group, represents ...
... University of York have made a huge leap forward in ... in the Department of Biology has made a significant advance ... of biological warfare. , Bacteria like E. coli frequently try ... antibiotics called colicins, which are potent toxins. , The ...
Cached Biology News:How satellite tracking revealed the migratory mysteries of endangered Atlantic loggerhead turtles 2Montreal researchers identify defects of immune cells 2
... BTX, the leader in electroporation products and ... innovative product line for experiment optimization and ... is a breakthrough in Molecular Delivery. The ... procedures that typically limited the number of ...
...
... analysis standard is a lyophilized ... molecular weights range from 69 ... provided for use with the ... organic acid analysis kit for ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Biology Products: